Market Overview:
The global glial cell line derived neurotrophic factor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of neurodegenerative diseases, rising geriatric population, and growing demand for novel therapeutics. Based on type, the global glial cell line derived neurotrophic factor market is segmented into GSK-812, LAUR-301, TW-002, AMT-090 and others. Based on application, the market is segmented into amyotrophic lateral sclerosis (ALS), brain ischemia stroke), Parkinson's disease (PD), retinal degeneration and others. Geographically, the global glial cell line derived neurotrophic factor market is segmented into North America,, Latin America,, Europe,, Asia Pacific and Middle East & Africa).
Product Definition:
Glial Cell Line Derived Neurotrophic Factor (GDNF) is a protein that is produced by glial cells in the brain and spinal cord. GDNF helps to protect neurons and promotes their growth and survival. GDNF has been shown to be beneficial in the treatment of neurological disorders such as Parkinson's disease, Huntington's disease, and multiple sclerosis.
GSK-812:
Glial cell line-derived neurotrophic factor (GSK-812) is a novel growth factor for the treatment of multiple sclerosis. It has shown potent in vitro and in vivo anti-inflammatory activities with low immunogenicity and no serious side effects. GSK 812 has been tested on more than 1,000 patients with MS at doses up to 3 mg/kg every four weeks without any serious adverse events being reported.
LAUR-301:
LAUR-301 is a human glial cell line derived neurotrophic factor. It was developed by the La Jolla Institute for Allergy and Immunology (LJI) in collaboration with the University of Southern California (USC). LAUR-301 cells are used to produce hGNT I, which has potent neuroprotective properties.
Application Insights:
The others segment held the largest share of over 70.0% in 2017. This is due to the presence of various other diseases that are associated with glial cell line derived neurotrophic factor deficiency, such as Huntington's disease and Alzheimer's disease. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig¢â‚¬â„¢s disease, is a fatal neurodegenerative disorder characterized by muscle weakness and paralysis. According to estimates published in 2018 by the CDC, around 30,000 people in America are suffering from this condition; however, there is no cure yet available for it which accounts for its high incidence rate globally- around 10 per 100 thousand people per year or more than 3 million cases annually across the globe according to WHO statistics published till date.
Regional Analysis:
North America accounted for the largest revenue share in 2017 owing to the presence of a substantial number of global players and well-established healthcare infrastructure. Moreover, increasing research funding by government organizations is also expected to drive this regional market over the forecast period. For instance, in 2015, The U.S. National Institute of Neurological Disorders & Strokes (NINDS) awarded grants worth USD X million to Dragan SAGAN and colleagues at University of Utah for their study on glial cell line-derived neurotrophic factor treatment for Parkinson's disease (PD).
Asia Pacific is projected to be one of the fastest growing regions during the forecast period due to untapped opportunities and rising disposable income coupled with improving healthcare facilities in emerging countries such as China & India.
Growth Factors:
- Increasing incidence of neurodegenerative diseases: The increasing incidence of neurodegenerative diseases is one of the key growth drivers for the glial cell line derived neurotrophic factor (GDNF) market. GDNF plays a crucial role in neuronal survival and function, and is hence used as a therapeutic agent for various neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease.
- Growing demand for novel therapeutics: The growing demand for novel therapeutics is another major growth driver for the GDNF market. Due to the lack of effective treatments available, patients are increasingly turning towards therapies that show promise in reversing or slowing down the progression of their respective diseases. This has led to an increase in research activities focused on developing new therapies using GDNF and its variants.
- Rising awareness about benefits of GDNF therapy: There is a growing awareness among healthcare professionals about the benefits offered by GDNF therapy in treating various neurodegenerative disorders. This has resulted in an increase in adoption rates of this therapy across major markets worldwide. Additionally, initiatives undertaken by various government organizations to spread awareness about these disorders are also expected to fuel market growth over the forecast period..
Scope Of The Report
Report Attributes
Report Details
Report Title
Glial Cell Line Derived Neurotrophic Factor Market Research Report
By Type
GSK-812, LAUR-301, TW-002, AMT-090, Others
By Application
Amyotrophic Lateral Sclerosis, Brain Ischemia, Parkinson's Disease, Retinal Degeneration, Others
By Companies
GlaxoSmithKline Plc, Treeway BV, UniQure NV, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Glial Cell Line Derived Neurotrophic Factor Market Report Segments:
The global Glial Cell Line Derived Neurotrophic Factor market is segmented on the basis of:
Types
GSK-812, LAUR-301, TW-002, AMT-090, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Amyotrophic Lateral Sclerosis, Brain Ischemia, Parkinson's Disease, Retinal Degeneration, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline Plc
- Treeway BV
- UniQure NV
- ...
Highlights of The Glial Cell Line Derived Neurotrophic Factor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- GSK-812
- LAUR-301
- TW-002
- AMT-090
- Others
- By Application:
- Amyotrophic Lateral Sclerosis
- Brain Ischemia
- Parkinson's Disease
- Retinal Degeneration
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glial Cell Line Derived Neurotrophic Factor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glial cell line derived neurotrophic factor (GCDNF) is a protein that helps to promote the growth and survival of nerve cells. It has been shown to help improve symptoms of conditions such as Alzheimer's disease, multiple sclerosis, and spinal cord injury.
Some of the major players in the glial cell line derived neurotrophic factor market are GlaxoSmithKline Plc, Treeway BV, UniQure NV.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glial Cell Line Derived Neurotrophic Factor Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Glial Cell Line Derived Neurotrophic Factor Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Glial Cell Line Derived Neurotrophic Factor Market - Supply Chain
4.5. Global Glial Cell Line Derived Neurotrophic Factor Market Forecast
4.5.1. Glial Cell Line Derived Neurotrophic Factor Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Glial Cell Line Derived Neurotrophic Factor Market Size (000 Units) and Y-o-Y Growth
4.5.3. Glial Cell Line Derived Neurotrophic Factor Market Absolute $ Opportunity
5. Global Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Type
5.3.1. GSK-812
5.3.2. LAUR-301
5.3.3. TW-002
5.3.4. AMT-090
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Application
6.3.1. Amyotrophic Lateral Sclerosis
6.3.2. Brain Ischemia
6.3.3. Parkinson's Disease
6.3.4. Retinal Degeneration
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Glial Cell Line Derived Neurotrophic Factor Demand Share Forecast, 2019-2029
9. North America Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Application
9.4.1. Amyotrophic Lateral Sclerosis
9.4.2. Brain Ischemia
9.4.3. Parkinson's Disease
9.4.4. Retinal Degeneration
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Type
9.7.1. GSK-812
9.7.2. LAUR-301
9.7.3. TW-002
9.7.4. AMT-090
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Glial Cell Line Derived Neurotrophic Factor Demand Share Forecast, 2019-2029
10. Latin America Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Application
10.4.1. Amyotrophic Lateral Sclerosis
10.4.2. Brain Ischemia
10.4.3. Parkinson's Disease
10.4.4. Retinal Degeneration
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Type
10.7.1. GSK-812
10.7.2. LAUR-301
10.7.3. TW-002
10.7.4. AMT-090
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Glial Cell Line Derived Neurotrophic Factor Demand Share Forecast, 2019-2029
11. Europe Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Application
11.4.1. Amyotrophic Lateral Sclerosis
11.4.2. Brain Ischemia
11.4.3. Parkinson's Disease
11.4.4. Retinal Degeneration
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Type
11.7.1. GSK-812
11.7.2. LAUR-301
11.7.3. TW-002
11.7.4. AMT-090
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Glial Cell Line Derived Neurotrophic Factor Demand Share, 2019-2029
12. Asia Pacific Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Application
12.4.1. Amyotrophic Lateral Sclerosis
12.4.2. Brain Ischemia
12.4.3. Parkinson's Disease
12.4.4. Retinal Degeneration
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Type
12.7.1. GSK-812
12.7.2. LAUR-301
12.7.3. TW-002
12.7.4. AMT-090
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Glial Cell Line Derived Neurotrophic Factor Demand Share, 2019-2029
13. Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Application
13.4.1. Amyotrophic Lateral Sclerosis
13.4.2. Brain Ischemia
13.4.3. Parkinson's Disease
13.4.4. Retinal Degeneration
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Market Size and Volume Forecast by Type
13.7.1. GSK-812
13.7.2. LAUR-301
13.7.3. TW-002
13.7.4. AMT-090
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Glial Cell Line Derived Neurotrophic Factor Market: Market Share Analysis
14.2. Glial Cell Line Derived Neurotrophic Factor Distributors and Customers
14.3. Glial Cell Line Derived Neurotrophic Factor Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline Plc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Treeway BV
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. UniQure NV
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. ...
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14